Should Newborns be Screened for Immunodeficiency? Lessons Learned from Infants with Recurrent Otitis Media

Otitis (David P. Skoner, Section Editor)

Abstract

Recurrent otitis media in children is considered one of the warning signs of primary immunodeficiencies (PIDs), particularly antibody deficiencies. Infants who have the most serious and potentially lethal form of PID, severe combined immunodeficiency (SCID), sometimes present with recurrent otitis media. Most of the time, because of the severity of the immune defect, they develop more serious and systemic infections. SCID is distinct among the PIDs and considered a pediatric emergency. Diagnosing SCID during the newborn period is crucial because survival completely depends on early diagnosis and treatment. Mortality declines significantly if immune reconstitution is established before 3.5 months of age, particularly before severe infections have occurred. However, most patients are diagnosed after they have suffered chronic or recurrent infections and developed permanent sequelae. Without institution of population-based newborn screening, most infants will miss the opportunity to live a healthy life.

Keywords

Otitis media Acute otitis media AOM Recurrent infections Primary immunodeficiencies Severe combined immunodeficiency SCID PID T-cell excision circles TRECs Newborn screening ADA deficiency Antibody deficiency Ataxia-telangiectasia Upper respiratory tract infections URI 

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Teele DW, Klein JO, Rosner B. Epidemiology of otitis media during the first seven years of life in children in greater Boston: a prospective, cohort study. J Infect Dis. 1989;160(1):83–94.PubMedCrossRefGoogle Scholar
  2. 2.
    Freid VM, Makuc DM, Rooks RN. Ambulatory health care visits by children: principal diagnosis and place of visit. Vital and health statistics. Series 13, Data from the National Health Survey. 1998;(137):1–23.Google Scholar
  3. 3.
    Berman S, Byrns PJ, Bondy J, Smith PJ, Lezotte D. Otitis media-related antibiotic prescribing patterns, outcomes, and expenditures in a pediatric Medicaid population. Pediatrics. 1997;100(4):585–92.PubMedCrossRefGoogle Scholar
  4. 4.
    Auinger P, Lanphear BP, Kalkwarf HJ, Mansour ME. Trends in otitis media among children in the United States. Pediatrics. 2003;112(3 Pt 1):514–20.PubMedCrossRefGoogle Scholar
  5. 5.
    Lanphear BP, Byrd RS, Auinger P, Hall CB. Increasing prevalence of recurrent otitis media among children in the United States. Pediatrics. 1997;99(3):E1.PubMedCrossRefGoogle Scholar
  6. 6.
    Skoner AR, Skoner KR, Skoner DP. Allergic rhinitis, histamine, and otitis media. Allergy Asthma Proc. 2009;30(5):470–81.PubMedCrossRefGoogle Scholar
  7. 7.
    Chonmaitree T, Revai K, Grady JJ, Clos A, Patel JA, Nair S, et al. Viral upper respiratory tract infection and otitis media complication in young children. Clin Infect Dis. 2008;46(6):815–23.PubMedCrossRefGoogle Scholar
  8. 8.
    Schwartz B, Giebink GS, Henderson FW, Reichler MR, Jereb J, Collet JP. Respiratory infections in day care. Pediatrics. 1994;94(6 Pt 2):1018–20.PubMedGoogle Scholar
  9. 9.
    • Gould JM, Matz PS. Otitis media. Pedia Rev/Am Acad Pedia. 2010;31(3):102–16. This is an excellent review on pediatric otitis media.CrossRefGoogle Scholar
  10. 10.
    •• Notarangelo LD, Fischer A, Geha RS, Casanova JL, Chapel H, Conley ME, et al. Primary immunodeficiencies: 2009 update. J Allergy Clin Immunol. 2009;124(6):1161–78. This is the most recent update on PIDs.PubMedCrossRefGoogle Scholar
  11. 11.
    Stiehm RE. The four most common pediatric immunodeficiencies. Ad Exp Med Biol. 2007;601:15–26.CrossRefGoogle Scholar
  12. 12.
    Boyle JM, Buckley RH. Population prevalence of diagnosed primary immunodeficiency diseases in the United States. J Clin Immunol. 2007;27(5):497–502.PubMedCrossRefGoogle Scholar
  13. 13.
    Bonilla FA, Geha RS. 12. Primary immunodeficiency diseases. J Allergy Clin Immunol. 2003;111(2 Suppl):S571–81.PubMedCrossRefGoogle Scholar
  14. 14.
    •• Notarangelo LD. Primary immunodeficiencies. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S182–94. This is an updated summary of recent progress on PIDs.PubMedCrossRefGoogle Scholar
  15. 15.
    Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol. 1999;92(1):34–48.PubMedCrossRefGoogle Scholar
  16. 16.
    Plebani A, Soresina A, Rondelli R, Amato GM, Azzari C, Cardinale F, et al. Clinical, immunological, and molecular analysis in a large cohort of patients with X-linked agammaglobulinemia: an Italian multicenter study. Clin Immunol. 2002;104(3):221–30.PubMedCrossRefGoogle Scholar
  17. 17.
    Vihinen M, Kwan SP, Lester T, Ochs HD, Resnick I, Valiaho J, et al. Mutations of the human BTK gene coding for bruton tyrosine kinase in X-linked agammaglobulinemia. Hum Mutat. 1999;13(4):280–5.PubMedCrossRefGoogle Scholar
  18. 18.
    Yong PF, Tarzi M, Chua I, Grimbacher B, Chee R. Common variable immunodeficiency: an update on etiology and management. Immunol Allergy Clin North America. 2008;28(2):367–86. ix-x.CrossRefGoogle Scholar
  19. 19.
    Latiff AH, Kerr MA. The clinical significance of immunoglobulin A deficiency. Ann Clin Biochem. 2007;44(Pt 2):131–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Boyle RJ, Le C, Balloch A, Tang ML. The clinical syndrome of specific antibody deficiency in children. Clin Exp Immunol. 2006;146(3):486–92.PubMedCrossRefGoogle Scholar
  21. 21.
    Buckley RH. Molecular defects in human severe combined immunodeficiency and approaches to immune reconstitution. Annu Rev Immunol. 2004;22:625–55.PubMedCrossRefGoogle Scholar
  22. 22.
    • Wilson NW, Hogan MB. Otitis media as a presenting complaint in childhood immunodeficiency diseases. Curr Allergy Asthma Rep. 2008;8(6):519–24. This article reviews the relationship between recurrent otitis media and PIDs.PubMedCrossRefGoogle Scholar
  23. 23.
    • Urschel S. Otitis media in children with congenital immunodeficiencies. Curr Allergy Asthma Rep. 2010;10(6):425–33. This is a review on pediatric otitis media in PIDs.PubMedCrossRefGoogle Scholar
  24. 24.
    Buckley RH. Primary immunodeficiency or not? Making the correct diagnosis. J Allergy Clin Immunol. 2006;117(4):756–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Kovanen PE, Leonard WJ. Cytokines and immunodeficiency diseases: critical roles of the gamma(c)-dependent cytokines interleukins 2, 4, 7, 9, 15, and 21, and their signaling pathways. Immunol Rev. 2004;202:67–83.PubMedCrossRefGoogle Scholar
  26. 26.
    Roberts JL, Lengi A, Brown SM, Chen M, Zhou YJ, O’Shea JJ, et al. Janus kinase 3 (JAK3) deficiency: clinical, immunologic, and molecular analyses of 10 patients and outcomes of stem cell transplantation. Blood. 2004;103(6):2009–18.PubMedCrossRefGoogle Scholar
  27. 27.
    Puel A, Ziegler SF, Buckley RH, Leonard WJ. Defective IL7R expression in T(−)B(+)NK(+) severe combined immunodeficiency. Nat Genet. 1998;20(4):394–7.PubMedCrossRefGoogle Scholar
  28. 28.
    Corneo B, Moshous D, Gungor T, Wulffraat N, Philippet P, Le Deist FL, et al. Identical mutations in RAG1 or RAG2 genes leading to defective V(D)J recombinase activity can cause either T-B-severe combined immune deficiency or Omenn syndrome. Blood. 2001;97(9):2772–6.PubMedCrossRefGoogle Scholar
  29. 29.
    Kung C, Pingel JT, Heikinheimo M, Klemola T, Varkila K, Yoo LI, et al. Mutations in the tyrosine phosphatase CD45 gene in a child with severe combined immunodeficiency disease. Nature Medicine. 2000;6(3):343–5.PubMedCrossRefGoogle Scholar
  30. 30.
    Moshous D, Callebaut I, de Chasseval R, Corneo B, Cavazzana-Calvo M, Le Deist F, et al. Artemis, a novel DNA double-strand break repair/V(D)J recombination protein, is mutated in human severe combined immune deficiency. Cell. 2001;105(2):177–86.PubMedCrossRefGoogle Scholar
  31. 31.
    Buck D, Moshous D, de Chasseval R, Ma Y, le Deist F, Cavazzana-Calvo M, et al. Severe combined immunodeficiency and microcephaly in siblings with hypomorphic mutations in DNA ligase IV. Eur J Immunol. 2006;36(1):224–35.PubMedCrossRefGoogle Scholar
  32. 32.
    Fischer A, de Saint Basile G, Le Deist F. CD3 deficiencies. Curr Opin Allergy Clin Immunol. 2005;5(6):491–5.PubMedCrossRefGoogle Scholar
  33. 33.
    •• Cossu F. Genetics of SCID. Ital J Pediatr. 2010;36:76. This is an excellent review of the genetics of SCID.PubMedCrossRefGoogle Scholar
  34. 34.
    Bluestone JA, Mackay CR, O’Shea JJ, Stockinger B. The functional plasticity of T cell subsets. Nat Rev Immunol. 2009;9(11):811–6.PubMedCrossRefGoogle Scholar
  35. 35.
    Wan YY. Multi-tasking of helper T cells. Immunology. 2010;130(2):166–71.PubMedCrossRefGoogle Scholar
  36. 36.
    Adeli MM, Buckley RH. Why newborn screening for severe combined immunodeficiency is essential: a case report. Pediatrics. 2010;126(2):e465–9.PubMedCrossRefGoogle Scholar
  37. 37.
    Shearer WT, Rosenblatt HM, Gelman RS, Oyomopito R, Plaeger S, Stiehm ER, et al. Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study. J Allergy Clin Immunol. 2003;112(5):973–80.PubMedCrossRefGoogle Scholar
  38. 38.
    Lindegren ML, Kobrynski L, Rasmussen SA, Moore CA, Grosse SD, Vanderford ML, et al. Applying public health strategies to primary immunodeficiency diseases: a potential approach to genetic disorders. MMWR. Recommendations and Reports : Morbidity and Mortality Weekly Report. Recommendations and Reports/Centers for Disease Control. 2004;53(RR-1):1–29Google Scholar
  39. 39.
    Myers LA, Patel DD, Puck JM, Buckley RH. Hematopoietic stem cell transplantation for severe combined immunodeficiency in the neonatal period leads to superior thymic output and improved survival. Blood. 2002;99(3):872–8.PubMedCrossRefGoogle Scholar
  40. 40.
    Aiuti A, Cattaneo F, Galimberti S, Benninghoff U, Cassani B, Callegaro L, et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. New Engl J Med. 2009;360(5):447–58.PubMedCrossRefGoogle Scholar
  41. 41.
    Hacein-Bey-Abina S, Hauer J, Lim A, Picard C, Wang GP, Berry CC, et al. Efficacy of gene therapy for X-linked severe combined immunodeficiency. New Engl J Med. 2010;363(4):355–64.PubMedCrossRefGoogle Scholar
  42. 42.
    Brown L, Xu-Bayford J, Allwood Z, Slatter M, Cant A, Davies EG, et al. Neonatal diagnosis of severe combined immunodeficiency leads to significantly improved survival outcome: the case for newborn screening. Blood. 2011;117(11):3243–6.PubMedCrossRefGoogle Scholar
  43. 43.
    Railey MD, Lokhnygina Y, Buckley RH. Long-term clinical outcome of patients with severe combined immunodeficiency who received related donor bone marrow transplants without pretransplant chemotherapy or post-transplant GVHD prophylaxis. J Pediatr. 2009;155(6):834–40. e1.PubMedCrossRefGoogle Scholar
  44. 44.
    Patel NC, Hertel PM, Estes MK, de la Morena M, Petru AM, Noroski LM, et al. Vaccine-acquired rotavirus in infants with severe combined immunodeficiency. New Engl J Med. 2010;362(4):314–9.PubMedCrossRefGoogle Scholar
  45. 45.
    Bakare N, Menschik D, Tiernan R, Hua W, Martin D. Severe combined immunodeficiency (SCID) and rotavirus vaccination: reports to the Vaccine Adverse Events Reporting System (VAERS). Vaccine. 2010;28(40):6609–12.PubMedCrossRefGoogle Scholar
  46. 46.
    Puck JM. Population-based newborn screening for severe combined immunodeficiency: steps toward implementation. J Allergy Clin Immunol. 2007;120(4):760–8.PubMedCrossRefGoogle Scholar
  47. 47.
    Chan A, Scalchunes C, Boyle M, Puck JM. Early vs. delayed diagnosis of severe combined immunodeficiency: a family perspective survey. Clin Immunol. 2011;138(1):3–8.PubMedCrossRefGoogle Scholar
  48. 48.
    Chan K, Puck JM. Development of population-based newborn screening for severe combined immunodeficiency. J Allergy Clin Immunol. 2005;115(2):391–8.PubMedCrossRefGoogle Scholar
  49. 49.
    Buckley RH, Schiff RI, Schiff SE, Markert ML, Williams LW, Harville TO, et al. Human severe combined immunodeficiency: genetic, phenotypic, and functional diversity in one hundred eight infants. J Pediatr. 1997;130(3):378–87.PubMedCrossRefGoogle Scholar
  50. 50.
    Routes JM, Grossman WJ, Verbsky J, Laessig RH, Hoffman GL, Brokopp CD, et al. Statewide newborn screening for severe T-cell lymphopenia. JAMA. 2009;302(22):2465–70.PubMedCrossRefGoogle Scholar
  51. 51.
    Comeau AM, Hale JE, Pai SY, Bonilla FA, Notarangelo LD, Pasternack MS, et al. Guidelines for implementation of population-based newborn screening for severe combined immunodeficiency. J Inherit Metab Dis. 2010;33 Suppl 2:S273–81.PubMedCrossRefGoogle Scholar
  52. 52.
    Hale JE, Bonilla FA, Pai SY, Gerstel-Thompson JL, Notarangelo LD, Eaton RB, et al. Identification of an infant with severe combined immunodeficiency by newborn screening. J Allergy Clin Immunol. 2010;126(5):1073–4.PubMedCrossRefGoogle Scholar
  53. 53.
    Dasouki M OK, Ray A, et al. Deficient T cekk receptor excision circles (TRECs) in autosomal recessive hyper IgE syndrome caused by DOCK8 mutation: implications for pathogenesis and potential detection by newborn screening. J Clin Immunol 2011; in press.Google Scholar
  54. 54.
    Azzari C, la Marca G, Resti M. Neonatal screening for severe combined immunodeficiency caused by an adenosine deaminase defect: a reliable and inexpensive method using tandem mass spectrometry. J Allergy Clin Immunol. 2011;127(6):1394–9.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Department of PediatricsWest Virginia University School of MedicineMorgantownUSA

Personalised recommendations